Latest Commercialization News

The Takeovers Panel has declined to intervene in PointsBet’s issuance of over 10 million new shares during a fierce takeover contest, affirming the board’s discretion amid competing bids from betr and MIXI Australia.

WestStar Industrial reports a 36% revenue decline and a $3.4 million net loss in FY25, driven by reduced activity at SIMPEC. New contract wins post-year-end signal a potential turnaround for FY26.

Wide Open Agriculture Limited has trimmed its annual loss to $7.09 million while expanding its lupin protein sales pipeline across key international markets and optimizing production in Germany.

Unith Ltd reported a 19% revenue increase to $5.37 million for FY25, driven by its new Digital Human platform launch and B2C expansion, yet net losses widened significantly to $4.95 million. The company’s strategic partnerships and capital raise underpin its growth ambitions amid ongoing cash burn.

Dataworks Group Limited reported a modest revenue increase and a reduced net loss for FY25, underpinned by major contract wins in Canada and Australia. The company is targeting cashflow positivity in the first half of FY26 following operational efficiencies and capital raises.

Papyrus Australia has marked significant progress in July 2025 with successful testing at its Rapid Prototyping facility and advancing plans for a commercial production site, while also writing down key investments.

Elanor Investors Group reported a substantial $157.8 million net loss for FY24 amid asset devaluations and debt covenant breaches, prompting a strategic recapitalisation and leadership transition.

ASF Group Limited reports a dramatic turnaround to a $25.8 million profit for FY2025, driven by a one-off $32.7 million gain from subsidiary disposals amid a 70% revenue drop.

Cardiex Limited’s FY2025 results reveal a sharp 67% revenue decline driven by the prior year’s one-off clinical trial payment, while net losses nearly doubled despite ongoing cost reduction efforts and significant capital raises.

Cambium Bio reported a $3.84 million loss for FY25 but secured critical FDA approvals and ethics clearances to initiate Phase 3 trials of Elate Ocular®, supported by a $2.12 million capital raise.

1414 Degrees Ltd reported a widened net loss of $3.34 million for FY25 while advancing its thermal energy storage and hydrogen reactor technologies, supported by fresh equity and government grants.

Firebrick Pharma reported a substantial increase in Nasodine Nasal Spray revenues in FY25, alongside a widening net loss driven by reduced R&D incentives and increased marketing investments. The company is advancing its international rollout with new licensing deals and board appointments.